StockData

Harmony Biosciences vs Nasus Pharma

HRMY and NSRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HRMY and NSRX compare

Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.9% compared with −0.47% at Nasus Pharma.

Harmony Biosciences scores higher on the StockData Score (18 against 6 for Nasus Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHRMYNSRX
Size and price
Market cap$1.9B–
Share price$33.01$2.61
Change, 1 year−3.0%−64.8%
Change, 5 years−12.1%–
Beta (5Y)1.111.84
Employees293–
StockData Score
Total score18 (better)6
Valuation score6 (better)0
Growth score2 (better)0
Performance score4 (better)1
Health score6 (better)5
Dividend score00
Valuation
P/E10.7×–
P/S2.0×–
P/B1.9×–
EV/EBITDA6.1×–
Fair value$53.99–
Margin of safety38.9%–
Growth
Revenue growth (TTM)24.3%–
Revenue growth, 5Y average40.3%–
Net income growth (TTM)0.20%–
EPS growth (TTM)−0.32%–
Profitability
Gross margin75.4%–
Operating margin24.0% (better)−0.40%
Net margin18.9% (better)−0.47%
FCF margin–−0.40%
Return on equity20.5% (better)−175%
Return on invested capital40.1%–
Financial health
Debt / equity0.15 (better)0.00
Net debt / EBITDA−2.23–
Interest coverage17.1×–
Current ratio3.488.77 (better)
Altman Z-score5.12–
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions93.0%23.9%
Held by insiders12.1%59.3%
Insider net buying, 12 months−$5.8M$61.8K (better)
Short interest, % of float13.0%1.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.